EANS-Adhoc: Marinomed Biotech AG: Greenshoe option fully exercised
Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.
Vienna – Vienna, 28 February 2019. Marinomed Biotech AG announces that the greenshoe option from the IPO of 39,000 shares at the offer price of EUR 75 per share was fully exercised. Erste Group Bank AG, acting as stabilising manager, has not conducted any stabilisation activities since the initial listing of the Marinomed shares on 1 February 2019.
After exercising the greenshoe option and subject to the registration of the capital increase in the commercial register planned for next week, the share capital amounts to EUR 1,469,772, split into 1,469,772 voting shares, and the free float amounts to around 39%.
About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com [http://www.marinomed.com/].
end of announcement euro adhoc
issuer: Marinomed Biotech AG
ISIN: ATMARINOMED6, AT0000A1WD52
Digital press kit: http://www.ots.at/pressemappe/31479/aom